HK Stock MarketDetailed Quotes

02269 WUXI BIO

Watchlist
  • 12.620
  • -0.620-4.68%
Market Closed Apr 19 16:08 CST
53.75BMarket Cap14.32P/E (TTM)

About WUXI BIO Company

The Group is the world's leading open biopharmaceutical technology platform company, providing end-to-end solutions for the discovery, development and production of biopharmaceuticals. Biopharmaceuticals are a subclassification of pharmaceuticals that have revolutionized the treatment of diseases in many major treatment fields around the world. The Group's end-to-end service platform enables it to provide services covering the entire biopharmaceutical development process and to provide customers with customized solutions according to their individual service requirements at any stage of the biopharmaceutical development process. The biopharmaceutical development process generally covers five stages: (i) drug discovery, (ii) preclinical development, (iii) early (phase I and II) clinical development, (iv) late stage (phase III) clinical development, and (v) commercial production. The services required for the biopharmaceutical development process can be divided into two categories: (1) pre-IND services, which include services provided in the first two stages of the biopharmaceutical development process, and (2) post-IND services, which include services provided in the remaining three stages of the biopharmaceutical development process. The Group's business model is based on its “follow the molecule” and “win the molecule” strategy. Customer demand for the Group's services will generally increase as their biopharmaceuticals advance through the biopharmaceutical development process and eventually commercialize production. As a result, the Group's revenue from each integrated project usually also increases as the project progresses.

Company Profile

Symbol02269
Company NameWUXI BIO
ISINKYG970081173
Listing DateJun 13, 2017
Issue Price20.60
Shares Offered192.98M share(s)
FoundedFeb 27, 2014
Registered AddressCayman Islands
Chairmange li
Secretaryyuecenyingwen huang
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficePO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands
Head Office and Principal Place of Business5/F, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees12740
MarketHong Kong motherboard
Phone(86)51085353482
Emailinfo@wuxibiologics.com
Business Yaoming Biotechnology Co., Ltd. is an investment holding company that mainly provides biologics discovery, development and production services. The company provides one-stop, end-to-end biopharmaceutical services through an integrated biopharmaceutical contract research, development and production organization (CRDMO) platform. The stages of the biopharmaceutical development process include pre-IND (drug discovery, pre-clinical development), early (phase I and II) clinical development, late stage (phase III) clinical development and commercial production. The company also provides end-to-end CRDMO services for vaccines, including vaccine discovery and development, scale-up of commercial production, and global distribution. The company has the WuxiBody bispecific antibody technology platform, the SDARbody multi-specific antibody technology platform, the WuxiUP continuous production platform, and the mRNA vaccine platform. The company mainly operates in domestic and overseas markets in China.

Company Executives

  • Name
  • Position
  • Salary
  • zhisheng chen
  • CEOs,Executive Director,Authorized Representative
  • --
  • weichang zhou
  • Honorary President of Global Biopharmaceutical Development and Operations,Non-executive directors,Senior Advisor to the CEO
  • --
  • ge li
  • presidencies,Non-executive directors,Chairman of the Nomination Committee
  • --
  • yibing wu
  • Non-executive directors
  • --
  • yanling cao
  • Non-executive directors
  • --
  • William Robert Keller
  • Independent Non-Executive Director,Remuneration Committee Chairman,Nomination Committee Members,Audit Committee Members
  • --
  • Kenneth Walton Hitchner III
  • Independent Non-Executive Director,Audit Committee Members,Remuneration Committee Members
  • --
  • guoliang dai
  • Independent Non-Executive Director,Chairman of the Audit Committee,Remuneration Committee Members,Nomination Committee Members
  • --
  • jue chen
  • Independent Non-Executive Director
  • --
  • Sherry Gu
  • Executive Vice President,chief technology officer,Head of Biopharmaceutical Development and Production
  • --
  • ming tu
  • Co-Chief Financial Officer
  • --
  • jijie gu
  • Executive Vice President,Chief Scientific Officer
  • --
  • jian dong
  • VP
  • --
  • xuejian xu
  • senior vice president,Chief Quality Officer
  • --
  • keqiang shen
  • Senior Vice President and Supervisor of China Biotech Manufacturing
  • --
  • William Aitchison
  • Senior Vice President of Global Manufacturing
  • --
  • Angus Scott Marshall Turner
  • VP
  • --
  • yingwen cen
  • Joint Company Secretary,Authorized Representative
  • --
  • yue huang
  • Joint Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg